Exocytosis of matrix metalloproteinases (MMPs) by pulmonary and systemic polymorphonuclear neutrophils (PMN) in hospital acquired pneumonia (HAP) Source: Eur Respir J 2002; 20: Suppl. 38, 585s Year: 2002
The difference of expression in TIMP-1, TIMP-2, and collagenase 1 at the idiopathic interstitial pneumonia Source: Eur Respir J 2002; 20: Suppl. 38, 478s Year: 2002
Matrix metalloproteinases (MMPs), tissue inhibitor of matrix metalloproteinases (TIMPs) and transforming growth factor-β (TGFβ) expression in small airways (SA) of usual idiopathic pneumonia (UIP), non-specific interstitial pneumonia (NSIP), hip Source: Annual Congress 2007 - Role of genomics and biological tools in the work-up of interstitial lung disease Year: 2007
Circulating matrix metalloproteinase-9 (MMP-9) is associated with the extension of lung disease in patients with active tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 35s Year: 2004
Defining stability in pneumonia and the non-responding pneumonia Source: Annual Congress 2005 - Outcome in severe pneumonia Year: 2005
The prognostic importance of plasma D-dimer levels in patients with community acquired pneumonia Source: Annual Congress 2007 - Prognostic laboratory tests in community-acquired pneumonia Year: 2007
Elevation of neutrophil collagenase (MMP-8) and elastase during COPD exacerbation Source: Annual Congress 2008 - Inflammatory trigger mechanisms in asthma and COPD Year: 2008
The discriminatory value of procalcitonin (PCT) and C-reactive protein (CRP) levels in HIV-seropositive patients presenting with community acquired pneumonia (CAP) due to pulmonary tuberculosis (PTB) compared with patients with pneumococcal pneumonia Source: Eur Respir J 2004; 24: Suppl. 48, 241s Year: 2004
Community acquired pneumonia (CAP) mortality and biomarkers Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia Year: 2011
Pulmonary apoptosis and related markers in ventilator acquired pneumonia (VAP) Source: Eur Respir J 2003; 22: Suppl. 45, 13s Year: 2003
Our experiences with cefriaxone in the treatment of hospital acquired pneumonias (HAP) Source: Eur Respir J 2002; 20: Suppl. 38, 357s Year: 2002
Soluble urokinase plasminogen activator receptor (suPAR) for the prediction of ventilator-associated pneumonia (VAP) Source: International Congress 2018 – Predicting the future: biomarkers of respiratory infection Year: 2018
The risk of bronchoalveolar fluid (BAF) contamination in ICU patients with infectious pulmonary complications Source: Annual Congress 2005 - Diagnosis and prognosis of ventilator associated pneumonia: the clinical track Year: 2005
Soluble form of CD95 (Fas/Apo-1) in patients with community-acquired pneumonia Source: Eur Respir J 2004; 24: Suppl. 48, 320s Year: 2004
Hyperglycaemia in children with community acquired pneumonia (CAP) Source: Eur Respir J 2003; 22: Suppl. 45, 318s Year: 2003
A prospective comparison of nursing home acquired pneumonia (NAP) with community acquired pneumonia (CAP) Source: Eur Respir J 2005; 26: Suppl. 49, 257s Year: 2005
Matrix metalloproteinases (MMPs) and angiogenesis in lung tissue remodeling in different variants of idiopathic interstitial pneumonia (IIP) Source: Eur Respir J 2007; 30: Suppl. 51, 137s Year: 2007
Characterization of community acquired pneumonia (CAP) with severe sepsis at diagnosis Source: Annual Congress 2012 - Epidemiology: risk factors and prognosis in respiratory infections Year: 2012
Community acquired pneumonia (CAP) 30 days mortality and biomarkers Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity Year: 2010
Effect of benzylpenicillin-ciprofloxacin vs. ceftriaxon-ciprofloxacin in treatment of massive pneumonia (CAP-community acquired pneumonia) Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections Year: 2011